Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
NCT02054806
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
477
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
BIOLOGICAL:
Pembrolizumab
Sponsor
Merck Sharp & Dohme LLC